Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Parexel
Time Perspective: Prospective for the majority of patients who are enrolled at the time they begin Nulojix (belatacept) treatment. Retrospective for any patients receiving Nulojix (belatacept) prior to enrollment into ENLiST Registry
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult kidney transplant recipient (age ≥18 years at time of transplant)
Kidney-only transplant recipient
Positive EBV serostatus
a) EBV serostatus negative or unknown included per the investigator discretion
Received first dose of Nulojix (Belatacept) within ≤ 14 days of renal transplant
Received first dose of Nulojix (Belatacept) as part of normal clinical care (i.e. not as part of a clinical trial)
You may not be if
Received Nulojix (belatacept) for non kidney transplants
\<18 years of age at time of transplant
Received first dose of Nulojix (belatacept) as an assigned study drug under a clinical trial protocol
EBV-serostatus negative or unknown patients, except by investigator decision
Patient who did not receive Belatacept for de novo treatment
Recipient of concurrent or extant non-kidney organ transplant
Received first dose of Nulojix (belatacept) \> 14 days after date of renal transplant
Clareo Health | Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
